EXPERT EVALUATION METHODOLOGY FOR GRADATION OF THE ANTHELMINTHIC MEDICINES ASSORTMENT ON THE PHARMACEUTICAL MARKET OF THE REPUBLIC OF UZBEKISTAN

Аннотация

This study presents a structured, mathematically grounded methodology for the systematic gradation and clinical prioritization of anthelminthic medicines available on the pharmaceutical market of the Republic of Uzbekistan. A purposively recruited expert panel of 68 highly qualified parasitologists and infectious disease specialists evaluated eight active pharmaceutical ingredients (INNs) using a weighted 5-point clinical utility scale and an extended 10-point multi-criteria assessment across eight primary consumer properties. Individual expert competence coefficients (S_p) were calculated and applied as weighting factors to minimize subjective bias. Consensus levels were quantified using the coefficient of variation (CV). Mathematical modeling results classified Albendazole and Mebendazole into Group 1 — 'Favorable Market Conjuncture' (CV ≤25%; composite index ≈0.87), establishing them as obligatory first-line therapeutic agents. Pyrantel, Niclosamide, and the Albendazole + Ivermectin combination were categorized into Group 2 ('Risk Group'), warranting epidemiology-guided procurement. Levamisole, Carbendazim, and the Albendazole + Levamisole combination were assigned to Group 3 — 'Unfavorable Market Conjuncture' (CV = 56–78%), with procurement strongly discouraged.